BillionToOne’s September insider sales versus Natera and Guardant

BillionToOne BillionToOne, Inc. sits in a part of healthcare where the market still pays for execution, not slogans. Molecular diagnostics has been one of the few corners of biotech where revenue growth can still command attention, and the peer set matters here. Natera is the obvious prenatal and oncology comparator. Guardant Health is the liquid biopsy name that keeps the market honest on what commercial adoption looks like when reimbursement, test volume, and margin all have to line up at once.

That is the frame for the September filings. The stock had already done the hard work. It closed at $98.77 on September 11, after a 52-week high near $150 in early August. So the insider sales did not arrive in a vacuum. They landed after a strong Q2, after a fresh Buy initiation from Canaccord Genuity with a $120 target on September 2, and after the market had already marked the name down from its post-earnings enthusiasm. That matters. A sale into a falling chart is one thing. A sale after a run, while the business is still growing fast, is another.

What the September sellers actually did

The filings were not subtle, but they were also not chaotic. John Roderick ten Bosch, SVP of Laboratory Operations, sold 1,416 Class A shares on September 9 at $97.54 each, for about EUR 118,739 euro-normalised filing value. The sale sat inside a pre-arranged Rule 10b5-1 plan adopted on June 2, 2026, and left him with 25,051 shares. That is a planned disposition, not a panic exit. Still, it is a sale by an operating executive in a name that has been telling the market it can scale.

David Tsao sold 20,000 shares the same day at an average $98.77, for about $1.975 million, and reduced direct holdings to 1,000 shares. Thomas Lynch disposed of 20,000 shares for roughly $2 million around September 8. Earlier August transactions by the CEO and others added to the pattern of planned dispositions. The cluster is not one person cashing out a token amount. It is several insiders, across a short window, selling into the same stock while the company is still in the middle of a strong operating run.

InsiderTrades data classifies this as a large-cap director-level cluster, with 4 distinct insiders and 12 recent declarations. The score rationale is plain enough: an operating director filed, the trades came as part of a cluster, and the euro-normalised filing value was small relative to the company, under 0.01% of market value. That is a useful way to keep the scale honest. EUR 118,739 sounds like money, because it is. Against a market value near EUR 3.79 billion, it is not a balance-sheet event.

BillionToOne’s growth is the reason the stock still matters

The reason this name stays on the screen is the business, not the filing. BillionToOne reported Q2 2026 revenue of $109.45 million, up 64% year over year, with billable test volume rising 35% and a swing to profitability. It reiterated full-year 2026 revenue guidance of $450 million to $465 million, which implies 48% to 52% growth. It also kept pushing the product set, launching Northstar Origin, a liquid biopsy add-on for tissue-of-origin identification, and expanding Northstar Select to 102 genes.

That is the sort of operating backdrop that keeps a diagnostics stock from being treated like a pure sentiment trade. The company is not asking the market to underwrite a distant platform dream. It is showing revenue, volume, and product expansion in the same quarter. That is why the stock could still command a $120 target from Canaccord even after the post-earnings pullback. The market is not paying for a perfect chart. It is paying for a company that can keep converting test volume into revenue and, now, into profit.

The peer comparison sharpens the point. Guardant Health has long been the liquid biopsy reference point, but it has also had to prove that oncology adoption can scale without the market getting ahead of itself. Natera has the prenatal franchise and oncology optionality, but it trades with its own set of reimbursement and adoption questions. BillionToOne is trying to occupy the middle ground, ultrasensitive prenatal testing through UNITY and oncology liquid biopsy through Northstar, with enough growth to stay in the conversation and enough commercial traction to avoid being dismissed as a science project.

The insider pattern versus the peer backdrop

This is where the comparison with Natera and Guardant matters. In a sector where the market tends to reward visible execution and punish any hint of slowing momentum, insider selling can mean several things. Sometimes it is just liquidity management after a run. Sometimes it is a sign that management thinks the stock has outrun the near-term setup. Here, the filings lean toward the first explanation, but they do not erase the second.

The sales were planned. That is the key detail. Ten Bosch sold under a 10b5-1 plan adopted in June. Tsao’s sale was also under a trading plan. Planned sales are not the same as discretionary dumping. They do, however, still tell you what insiders were willing to do with their stock when the window opened. In a name that had already climbed to an early-August high near $150 before sliding back to $98.77, that willingness matters more than the mechanical label on the filing.

InsiderTrades data gives you a useful historical anchor here. The relevant bucket, director-level buys at large-cap names, has a 55.7% 90-day win rate and a 3.32% average 90-day return across 5,415 observations. That is historical cohort data, not a forecast for BillionToOne, and it should not be treated like one. But it does tell you that this kind of trade bucket has not been noise in our sample. It has had a modest positive drift over 90 days. Not a promise. A context line.

Valuation, execution, and why the stock still has room to disappoint

BillionToOne’s market value near EUR 3.79 billion gives the stock room to move, but it also gives it room to disappoint. The company’s fundamental score is 43, with quality at 49 and value at 37. That is not a disaster. It is also not the sort of profile that lets a stock coast on momentum alone. The market has already rewarded the growth. Now it wants continued execution, and it wants it without margin slippage or a slowdown in test adoption.

The valuation question is not abstract in this peer group. Natera and Guardant both trade in a world where investors constantly reprice the balance between growth and proof. BillionToOne has the advantage of a strong quarter and a fresh product cadence. It also has the burden of being a name that has run enough for insiders to sell into strength. That combination is common in diagnostics. It is also where the market gets picky. If growth stays above 50% and profitability holds, the stock can keep its premium. If either slips, the multiple can compress quickly.

The insider sales do not change that math on their own. They do, however, tell you that management is not behaving as if the stock is obviously cheap. That is not a moral judgment. It is a market one. When a CTO sells 20,000 shares and ends up with 1,000 direct shares, while another executive sells roughly $2 million around the same time, you are looking at a group that is comfortable monetizing part of the move. In a fast-growing diagnostics name, that is a data point worth respecting.

What the cluster says when you put it next to the business

The cluster picture is the part that keeps this from being a one-line filing story. InsiderTrades data shows 12 recent declarations from 4 distinct insiders, including multiple September entries from Tsao and a sale from ten Bosch, plus earlier August activity from the CEO and others. That is enough to say the selling was not isolated. It was coordinated by calendar, if not by intent, because the trading plans and filing dates line up across a short span.

Against the business backdrop, though, the cluster is not a clean bearish tell. BillionToOne is still growing revenue at 64%, still expanding product breadth, and still guiding to 48% to 52% full-year growth. In a sector where many names are still fighting for commercial credibility, that matters. The market is not being asked to believe in a future platform. It is being asked to price a company that is already shipping growth.

That is why the comparison to Guardant and Natera is useful. Those names have taught the market to separate science from scale, and scale from margin. BillionToOne now has to do the same. The insider cluster says the people filing the forms are willing to sell after the stock has already done a lot of work. The operating results say the company still has enough momentum to justify attention. Both can be true. You do not need to force them into the same conclusion.

The next print matters more than the filing window

The next thing to watch is not whether another insider sale appears. There may be more. The trading plans already tell you the window is open. What matters is whether the company can keep the Q2 cadence into the next print without leaning on one-off enthusiasm. Revenue growth, billable test volume, and the Northstar rollout are the real markers. If those keep moving in the right direction, the September sales will look like planned monetization after a strong run. If they do not, the same filings will look more like insiders taking advantage of a rich window.

The market already gave you one clue by pulling the stock back from the early-August high near $150 to $98.77 on September 11. That reset gives the company less room for error and more room for proof. It also makes the peer comparison sharper. Natera and Guardant are still the names that define how the market prices precision diagnostics. BillionToOne is trying to earn a seat at that table with faster growth and a cleaner profitability story. The September selling cluster does not change that contest. It just tells you management was willing to sell while it was still in progress.

This is where the insider filing is useful, and where it stops. It tells you that several executives chose to monetize part of their holdings after a strong quarter and after the stock had already run. It does not tell you the next quarter’s revenue. It does not tell you whether the market will keep paying up for ultrasensitive prenatal testing and oncology liquid biopsy. It does tell you that the stock is no longer cheap enough for insiders to ignore the window.

This is not investment advice.